Trending Now
  • Consumer Legal Funding Is Not the Problem Facing America’s Truckers
  • Rowling Foundation Offers to Fund NHS Single-Sex Space Challenges
Commercial Special Features

Key Takeaways from LFJs Special Digital Event: Mass Torts and Litigation Funding 

March 28, 2023

Key Takeaways from LFJs Special Digital Event: Mass Torts and Litigation Funding 

On Thursday March 23rd, Litigation Finance Journal hosted a special digital event: Mass Torts and Litigation Funding. Panelists included Michael Rozen (MR), Founder and Managing Partner at TRGP Investment Partners, James Romeo (JR), Managing Partner at Greenpoint Capital, Brian Roth (BR), Chief Executive Officer and Chief Investment Officer of Rocade Capital, and Michael Guzman (MG), Partner at Kellogg, Hansen, Todd, Figel and Frederick. The discussion was moderated by Ed Truant (ET), Founder of Slingshot Capital.

The panel discussion spanned a range of topics, including claims origination, financing/underwriting, plaintiff and defense-side strategies and tactics, the impact of ABS regulation and much more. 

Below are some key takeaways: 

ET: How does the industry originate claims and identify and validate claimants? And how has origination industry evolved over the years from the time of mass TV advertising to the current omni-channel world of advertising? 

MG: First, all of the old traditional methods still work.  Networking, late night TV, radio, advertising – all of that still works. But what I am seeing is a number of firms have either affiliated with or own social media marketers, who are using social media in targeted ways. It’s a lot cheaper depending on how you use it, and it can be a lot faster. So people are using the old techniques, plus a number of new ones.  I’ve had some really good success with that, because you’re not just blanketing the airwaves, the people that you get back are much more focused and more interested in what it is you’re trying to recruit them for. 

JR: I think it’s helpful to go back and think about the history of legal advertising, which started in the late 70’s when two lawyers started advertising, it led to some fighting in the state bar, but ultimately it was decided that legal ads are a form of free speech and that they provide consumers valuable information. 

We’ve now seen this huge evolution around what’s possible. There is very targeted social media and paid search advertising that is driven by analytics. At Triton we’re doing a lot of this, we’ve developed our own in-house marketing team, and we’re using things like intake forms and chatbots to help pre-screen potential claimants. We’re using different identify verification tools and we’re experimenting with different medical retrieval tools to help with the intake of potential claimants. 

ET: Describe the ‘fall-out rate’ of claimants and what are typical fall-out rates evidenced in the market and reasons therefor? Has there been an improvement in fall-out rates as a result of enhanced data analytics and technological sophistication?

MR: Access to justice is always a goal for those who think that corporate America has long gotten away with unequal justice because they have a lot of money and the individual claimants don’t. So having better ways of reaching people who may have been impacted by a drug that’s been pulled from the market or a product that didn’t work as advertised is obviously a good thing. The flip side is, in tougher economic times, you see higher claim rates from people who may not be good claimants, because there is an expectation there may be some quick money to be obtained. 

So I think the fall-out rate is really a function of whether or not you’re in the right economic time with the right kind of claim. Camp Lejeune is an example of that. 3M earplugs is an example of that. We’re talking about hundreds of thousands of claimants, whereas in an ordinary mass tort you may have tens of thousands of claimants. And this is something defendants don’t like, and they push back on litigation finance in particular, and argue that somehow specious claims are being promoted. What is really at the base of that is a desire to create an unequal footing between the haves and the have nots. If you are on the have side, it is obviously to your benefit to have either lower claim rates, fewer number of plaintiffs, and/or a higher fallout rate where you can allege later on that these were not valid claimants, that they were somehow propped by third party financing. 

Nobody who has or will speak on this panel will tell you that investing in non-meritorious claims is a good thing. Yet what the other side of this argument will claim is that somehow the fall-out rate as an individual metric is indicative of whether or not there are valid claims in a particular litigation. I would say you to it is irrelevant—the more claims you have in a litigation, the higher the fall our rate is going to be. 

ET: Given the high fall-out rates and the potential for false claimants, is this sector ripe for the application of blockchain to minimize duplication of claimants and decrease fall-out rates as well as tracking the transactions and pay-outs? 

 BR: Fall out impacts the litigation strategy and settlement strategy. When a litigation starts, nobody really knows what will be a settle-able case, so there’s always going to be some level of origination that’s not going to result in a paid claim at the end of the day. I do think the technology will help with some areas like de-duplication and dual representation, whether it’s blockchain or other smart contracts. We’re seeing billions of dollars transact in the space and there’s very little transparency across the different players in the space. I see that changing over time, and that will impact the fall out rates as well. 

ET: What is the nature of the prototypical plaintiff litigation firm? Why do so called “White Shoe” law firms not get involved in mass tort plaintiff litigation work? 

MG: When I started my career, there was this perception that there were defense-side firms and plaintiff-side firms. Lines were pretty well drawn, people crossed over from time to time. But for the most part, if you did plaintiff’s work you did plaintiff’s work, and you didn’t go back and forth. My firm and lots of others defy that model, and at this point, I’m not sure there is a prototypical plaintiff’s firm. My firm is a litigation boutique, and very early on we realized some of our clients wanted us to be plaintiffs for them, and it was enormously challenging and lucrative to play that role for them.

I think why so many of the so-called ‘white shoe’ law firms have found it difficult to be a plaintiff-side firm is because they have corporate departments or longstanding institutional clients, and some of those clients just don’t like the idea that one of those partner is representing them, but at the same time someone else is off pursuing a mass action or class action, so it gets to be an institutional conflict—it’s hard to manage from a client standpoint, and we’ve dealt with that over the years. 

ET: How has the US mass tort industry evolved in terms of the size of the industry, the quantum of cases and the number of claimants over the years? 

JR: If you look at the federal docket, it took something like 59 years to reach the first 250,000 cases in MDLs, and over the subsequent seven years, from 2007-2014, we hit a total of half a million cases, and then by 2021, we topped 1 million cases. So that’s an additional 500,000 case jump from 2014 to 2021. And there’s currently something like 360,000 cases that are still pending in the federal docket. So there’s definitely been an acceleration of cases, and that’s continued. And I don’t see that sopping any time soon. 

ET: Can you describe the various ways in which finance intersects with the mass tort industry?

BR: Financing is an ever changing landscape, but at the front end, you’re seeing it for case origination, a lot of times it’s done on a non-recourse basis. We see a lot of law firm loans, where you’re financing the whole process from origination to settlement. We’re also seeing capital enter for service providers in the space – lead origination or working up cases, ordering records on a contingent basis. We’re also starting to see some post-settlement finance develop, where firms are basically able to factor their claims. 

As we think about the space, we expect this to continue to evolve and develop, and this matures as an asset class, and we develop more data and track records, you’ll see more segmentation I think. But that should translate into more flexible options for the firm. The space currently is shaped by the rules around fee sharing and the ethical rules for law firms which prevent non-lawyers from having ownership in the firm. Obviously, Arizona and other jurisdictions are changing that, so the landscape of how finance intersects with firms is changing as well. 

Commercial

View All
Commercial

Op-Ed Ties California Litigation Costs to Rising Cost of Living

A commentary published this week argues that California's litigation environment functions as an unofficial tax on businesses and consumers, adding to the state's cost of living at a moment when affordability dominates its politics.

As reported by California Globe, the piece by John Allard, a former mayor of Roseville with more than two decades as a small business owner, sets national tort costs at $529 billion in 2022, equivalent to 2.1% of GDP, and cites projections that the figure could exceed $900 billion by 2030. Within California, the author points to 199 nuclear verdicts between 2013 and 2022 totalling more than $9 billion.

Much of the argument focuses on state-specific mechanisms. Allard highlights the Private Attorneys General Act, noting that claims routed through the state review process resolve 52% faster while workers receive 67% less compensation than in court-filed claims, and describes Proposition 65 as having produced an industry of citizen enforcers, with settlements rising from $26 million across 890 settlements in 2022 to more than $101 million across over 1,300 settlements more recently. The commentary also flags the Gilead "duty to innovate" case as an example of novel liability theories reaching the state's highest court.

Third-party litigation funding appears only in passing, referenced in connection with Georgia's 2025 reforms rather than through California-specific data. That absence is itself notable: the state has no funding disclosure or registration statute, and the op-ed offers no estimate of funded case volume within its cost figures.

The piece is advocacy rather than analysis, and its figures come from tort reform sources whose methodology has been contested. It nonetheless illustrates how the cost-of-living frame is being applied to litigation policy in the largest state yet to legislate on funding, and where a disclosure debate has so far failed to gain traction.

Commercial

Novarex Capital Partners Closes Initial £5 Million Funding Round

London-based Novarex Capital Partners has completed an initial £5 million funding round, with a second round already underway as part of a broader capital programme.

According to ACCESS Newswire, the firm describes itself as a specialist introduction platform focused on private credit, litigation finance and structured capital, identifying opportunities for sophisticated investors seeking access to private markets. The proceeds of the initial round support the working capital requirements of an SRA-regulated law firm engaged in the preparation of eligible claims, operating in accordance with SRA standards and maintaining professional indemnity insurance.

The company said each stage of funding is designed to align with operational requirements while adhering to relevant regulatory frameworks. A second round is advancing, with a further round planned.

The structure reflects a financing model that has become increasingly common in the UK claims market, where capital is deployed against a law firm's working capital needs during claim preparation rather than committed to individual matters. That approach places the funder's exposure at the firm level, tied to the pace at which eligible claims are built and progressed, and depends heavily on the quality of the underlying claim pipeline and the discipline of the regulated firm carrying out the work.

The raise is modest by the standards of the institutional funds that have dominated recent fundraising headlines, but it sits in a segment of the UK market that has drawn scrutiny following a series of failures among smaller funders and claims businesses over the past year. Whether Novarex's staged capital programme reaches its later rounds will offer some indication of investor appetite for law firm working capital exposure at a moment when that risk is under closer examination.

Commercial

Auto Injury Claim Costs Outpaced Medical Inflation for Five Straight Years, Study Finds

Average payments on U.S. auto bodily injury claims rose at more than double the rate of medical care inflation between 2017 and 2022, according to a new Insurance Research Council study drawn from one of the largest claims datasets assembled for the line.

As reported by Insurance Business, the IRC analysed more than 7.4 million auto injury claims closed with payment over the five-year window, pooled from nine insurers representing roughly 43% of the U.S. private passenger auto market. Average bodily injury claim payments climbed from approximately $14,000 in 2017 to more than $20,000 in 2022, an annualised increase of 7.8% that accelerated markedly after 2020.

The study points to attorney involvement as a central variable. Legal representation among claimants rose from 40% in 2017 to nearly 50% by 2022, with bodily injury claimants showing the sharpest movement at 11 percentage points, while litigation rates nearly doubled from 10% to 18%. Medical bills increasingly functioned as a multiplier rather than a fixed cost: for each dollar of medical expense, total settlement value rose from $1.80 in 2017 to $2.30 by 2022.

The outcomes data complicates the picture for claimants. Represented claimants saw median closure times of 440 days against under 220 days for unrepresented claimants, and after accounting for medical costs and legal fees, netted $1.40 per dollar of medical bills compared with $1.80 for those without representation. IRC's Patrick Schmid tied the trend to settlement pressures and their downstream effect on auto insurance affordability.

The findings arrive as insurers and trade groups press state and federal lawmakers on third-party litigation funding disclosure, and the report's framing of structural cost drivers is likely to feature in that argument. The dataset's scale gives the numbers unusual weight in a debate that has often turned on contested estimates.